Truist raised the firm’s price target on AbbVie to $210 from $195 and keeps a Buy rating on the shares. The company’s “strong” Q2 revenue and earnings beats were led by Skyrizi/Rinvoq, the analyst tells investors in a research note. Truist also sees strong performance across AbbVie’s diversified portfolio, with potential for ongoing growth into the end of the decade, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- ABBV Earnings: AbbVie Exceeds Q2 Expectations Driven by Strong Immunology Sales
- AbbVie sees FY24 revenue approximately $55.5B, consensus $50.87B
- AbbVie sees FY24 gross margin 84% of sales
- AbbVie sees Q3 adjusted EPS $2.92-$2.96, consensus $2.68
- AbbVie: Discontinuing development of ABBV-916 as standalone antibody